HumaScan receives warning letter

Article

HumaScan's marketing efforts for its BreastAlert Differential Temperature Sensor (DTS) system have drawn the attention of the Food and Drug Administration. In an April 24 warning letter to the Cranford, NJ-based company, the agency's Center for Devices

HumaScan's marketing efforts for its BreastAlert Differential Temperature Sensor (DTS) system have drawn the attention of the Food and Drug Administration. In an April 24 warning letter to the Cranford, NJ-based company, the agency's Center for Devices and Radiological Health took issue with advertisements, physician labeling, comments by celebrity spokespersons, and press releases associated with BreastAlert, a noninvasive adjunctive screening device for breast cancer (SCAN 7/9/97). HumaScan holds U.S. and Canadian marketing rights from Scantek Medical, which developed the product.

In particular, the CDRH's warning letter stated that the company has misrepresented the intended use of the device, making both implicit and explicit claims that the device can detect breast disease, including breast cancer. The device was cleared as an adjunct to routine physical examination, including palpation, mammography, and other established procedures for the detection of breast disease. HumaScan officials were not immediately available for comment.

In other company news, HumaScan and BreastAlert's developer, Scantek Medical of Denville, NJ, have restructured their licensing agreement. The move, which was made to provide HumaScan with additional time and financing to pursue its marketing and distribution plans, waives certain HumaScan royalty payments in exchange for HumaScan stock warrants.

HumaScan has also restructured its contract with Zigmed, which provides production equipment for BreastAlert. The purchase price for the equipment has been reduced by approximately $200,000 in exchange for the issuance of warrants to purchase 30,000 shares of HumaScan's common stock at $4.725 per share.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.